Iris Dirven

9PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicineMedical mycologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 26, 2026
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review.

|Mar 14, 2026
The Effectiveness of a Multidisciplinary Integrative Survivorship Program for Cancer-Related Cognitive Impairment: A Prospective Cohort Study.

Nathalie Vanlaer, Camille Testaferrata, Lynn Decabooter

|Dec 17, 2024
Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases.

Iris Dirven, Eden Pierre, An-Sofie Vander Mijnsbrugge

|Oct 07, 2024
Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT).

Gil Awada, Iris Dirven, Julia Katharina Schwarze

|Jul 11, 2024
Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series.

Iris Dirven, Manon Vounckx, Jolien I Kessels

|May 11, 2024
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study.

Nathalie Vanlaer, Iris Dirven, Bart Neyns

Pageof 2

Frequent Collaborators

7 joint publications

Bart Neyns

2 joint publications

Nathalie Vanlaer

2 joint publications

Anne Rogiers

2 joint publications

Cleo Bertels